cobas KRAS Mutation Test
Roche Molecular Systems, Inc. · Decision date Oct 27, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice supplement, P140023/S033, for the cobas® KRAS Mutation Test, a somatic gene mutation detection system in the pathology specialty under product code OWD. The applicant is Roche Molecular Systems, Inc. The listed decision is OK30, dated 2026-10-27.
The recorded statement describes a change to the manufacturing process for oligonucleotides. This supplement concerns that process change, categorized as a manufacturer, sterilizer, packager or supplier change, and does not represent approval of the whole test system. The source record includes no supporting documents, so the specific oligonucleotides, process steps and any performance data remain unknown.
FDA approval order statement
to change the manufacturing process for oligonucleotides
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140023/S033
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140023 · Original PMA
COBAS KRAS MUTATION TEST
P140023/S033 received
Application receipt date recorded by FDA.
P140023/S033 · FDA decision
30-Day Notice
P140023/S034 · Related supplement
Roche cobas KRAS Mutation Test
Timeline entries are records held by MedtechLedger for P140023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS KRAS MUTATION TESTP140023 | Roche Molecular Systems, Inc. | PMA approval | May 7, 2015 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P140023/S033
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



